Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)
- 1 February 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 23 (5) , 623-628
Abstract
SARS-CoV-2, the virus that causes COVID-19, elicits a variety of host responses ranging from asymptomatic or mild illness in most people, to severe disease and critical illness in a subset of patie...Keywords
This publication has 62 references indexed in Scilit:
- Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat.2016
- Clinical Asthma Phenotypes and Therapeutic ResponsesISRN Pediatrics, 2013
- Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add‐on therapyBritish Journal of Clinical Pharmacology, 2012
- Suppression of Inflammatory Cytokine Secretion by an NF-?B Inhibitor DHMEQ in Nasal Polyps FibroblastsCellular Physiology and Biochemistry, 2012
- Glucocorticoid-regulated genes in eosinophilic esophagitis: A role for FKBP51Journal of Allergy and Clinical Immunology, 2010
- Children in the ACT with asthma--are they taking preventer medication according to guidelines?2010
- Dynamic Changes in Clinical Features and Cytokine/Chemokine Responses in Sars Patients Treated with Interferon Alfacon-1 plus CorticosteroidsAntiviral Therapy, 2005
- Expression of a high-affinity serotonin transporter in human lymphocytesInternational Journal of Immunopharmacology, 1994
- FLUVOXAMINE, A SPECIFIC 5‐HYDROXYTRYPTAMINE UPTAKE INHIBITORBritish Journal of Pharmacology, 1977
- Fluvoxamine?A new serotonin re-uptake inhibitor: First clinical and psychometric experiences in depressed patientsJournal of Neural Transmission, 1977